WIN-Partners (3183) FY2026 Q3 Earnings Report

Quick View

Executive Summary

Revenue increased substantially by 9.7% YoY, while Operating Income rose by 8.0%, resulting in a higher-revenue, higher-profit performance in which revenue growth was converted into profit growth at approximately the same rate. Revenue was ¥662.8B, Operating Income was ¥22.3B, Ordinary Income was ¥22.6B, and Net Income attributable to shareholders of the parent company was ¥15.3B. The Operating Margin was 3.4%, approximately 5bp lower than in the same period of the previous year, indicating that margins have not improved to the same extent as revenue expansion.

Factors Affecting Performance

【Revenue】Revenue was ¥662.8B (+9.7% YoY), with progress toward the full-year company forecast of ¥835.0B (+2.6% YoY) at 79.4%, exceeding the standard progress benchmark of 75%. The Company operates as a single segment, the Medical Equipment Sales Business, and expanding demand is believed to be the primary driver of revenue growth.

【Earnings】Operating Income was ¥22.3B (+8.0% YoY), Ordinary Income was ¥22.6B (+8.5% YoY), and Net Income was ¥15.3B (+8.3% YoY). Non-operating income and expenses made a slight positive contribution of ¥0.4B, primarily from interest income. Extraordinary gains and losses were nearly offset by a ¥0.1B gain on the sale of fixed assets and ¥0.1B in extraordinary losses, meaning that Net Income largely reflects recurring business earnings. Within a low-margin structure comprising a gross margin of 11.8% and an SG&A ratio of 8.4%, the Operating Margin declined slightly year on year. Although the Company recorded higher revenue and higher profit, the rate at which revenue growth translated into profit growth was limited. In conclusion, the Company recorded higher revenue and higher profit.

Segment Analysis

The Group operates as a single segment, the Medical Equipment Sales Business, and does not disclose segment-level operating income or loss.

Key Financial Indicators

【Profitability】The Operating Margin of 3.4% and Net Profit Margin of 2.3% both declined slightly from the same period of the previous year, while the gross margin of 11.8% remains the primary constraint on profitability. 【Cash Quality】Trade receivables—comprising accounts receivable of ¥170.0B and electronically recorded monetary claims of ¥30.2B—totaled ¥200.3B. DSO calculated relative to revenue was approximately 70 days, making the efficiency of receivables collection during a period of 9.7% revenue growth a key area of focus. 【Investment Efficiency】ROE was 6.6%, decomposed into a Net Profit Margin of 2.3% × total asset turnover of 1.37x × financial leverage of 2.10x. The primary constraint on capital efficiency is the low Net Profit Margin. 【Financial Soundness】The Equity Ratio of 47.6%, current ratio of 178.2%, and quick ratio of 162.4% were all at sound levels. Cash and deposits of ¥148.9B covered 63.8% of current liabilities of ¥233.4B.

Cash Flow Analysis

The current earnings data do not include figures for Operating Cash Flow (OCF), investing cash flow, or financing cash flow in the cash flow statement; accordingly, funding trends are analyzed based on changes in the balance sheet. Cash and deposits were ¥148.9B, down from ¥162.1B in the previous year. Accounts receivable increased to ¥170.0B from ¥162.6B in the previous year, while electronically recorded monetary claims increased to ¥30.2B from ¥25.4B. As trade receivables increased at least as rapidly as revenue, which grew by 9.7%, revenue growth may be accumulating in working capital ahead of cash conversion. Meanwhile, accounts payable increased to ¥191.4B from ¥172.1B in the previous year, with the expansion of trade payables financing a certain portion of the increase in working capital.

Quality of Earnings

The gap between Ordinary Income and Net Income reflects the normal tax burden of ¥7.3B in income taxes and other taxes, equivalent to an effective tax rate of 32.3%, with few special adjustment factors. Extraordinary income of ¥0.1B from the sale of fixed assets was nearly offset by ¥0.1B in extraordinary losses, and Net Income of ¥15.3B was generated largely from recurring business activities. Non-operating income of ¥0.4B was primarily interest income and was not large enough to materially supplement the core business; most earnings were derived from Operating Income. Comprehensive income was ¥15.1B, close to Net Income of ¥15.3B, indicating that the divergence caused by valuation differences on securities and adjustments for retirement benefits was limited. From an accruals perspective, the increase in trade receivables may have exceeded the pace of earnings growth, making DSO trends an important factor to monitor when assessing earnings quality.

Earnings Forecast and Guidance

Progress toward the full-year company forecast was 79.4% for Revenue, 74.3% for Operating Income, 74.6% for Ordinary Income, and 74.5% for Net Income. Revenue is ahead of the standard progress benchmark of 75%, while the profit items are generally tracking in line with plan. The forecast full-year Operating Margin of 3.59% exceeds the Q3 cumulative actual result of 3.36%, requiring an improvement in gross margin or greater SG&A efficiency in Q4. To achieve the full-year forecast, the Company must record Operating Income of ¥7.7B and Net Income of ¥5.2B in Q4. These amounts correspond to the 25% range of the full-year forecast and are consistent with the progress achieved to date.

Shareholder Returns

The Q2 dividend was ¥0, and the full-year dividend forecast is ¥54.0 per share. The Payout Ratio relative to forecast full-year EPS of ¥71.7 is 75.3%, a relatively high level based on dividends alone. Treasury stock of ¥2.09B is recorded, but the acquisition amount for the current period has not been disclosed; therefore, the Total Return Ratio including share repurchases has not been calculated. Dividend sustainability depends on the extent to which the full-year Net Income forecast of ¥20.5B is achieved.

Risk Factors

1. Low-Margin Structure Risk: Under a low-margin structure with a gross margin of 11.8% and an Operating Margin of 3.4%, even small fluctuations in procurement prices, selling prices, product mix, logistics expenses, or personnel expenses can have a relatively large impact on margins. The Operating Margin declined by approximately 5bp year on year.

2. Trade Receivables Collection Risk: Trade receivables, comprising accounts receivable of ¥170.0B and electronically recorded monetary claims of ¥30.2B, totaled ¥200.3B, with DSO at approximately 70 days. If receivables collection is delayed during a period of 9.7% revenue growth, the resulting increase in working capital requirements could cause Operating Cash Flow to lag Net Income.

3. Single-Business Structure Risk: As the Company operates as a single segment, the Medical Equipment Sales Business, it has no other business through which to offset supply-demand fluctuations affecting specific product groups, suppliers, or customer channels, or revisions to medical insurance reimbursement prices. Consequently, the impact on performance may become concentrated.

Industry Benchmark (For Reference; Company Research)

Profitability and Returns

The Operating Margin is in line with the industry median, while the Net Profit Margin is below the median, suggesting relative underperformance in non-operating items and tax burden.

Growth and Capital Efficiency

The Revenue Growth Rate exceeds the upper bound of the industry IQR, indicating a high growth rate relative to peers.

※Source: Company research

Key Takeaways from the Earnings Results

1. Revenue increased by 9.7% YoY, exceeding the industry median of 5.2%, but the Operating Margin declined slightly from the same period of the previous year. The rate at which revenue growth translates into profit growth will therefore be a key focus.

2. Trade receivables (accounts receivable + electronically recorded monetary claims) totaled ¥200.3B, with DSO reaching approximately 70 days. The increase in working capital and the speed of cash conversion during a period of revenue growth will be important areas to monitor.

3. While progress toward the full-year forecast was ahead for Revenue at 79.4%, progress for Operating Income was 74.3%, broadly in line with plan. Margin improvement in Q4 will be critical to achieving the forecast full-year Operating Margin of 3.59%.

Theoretical Share Price (For Reference)

Sensitivity: ¥791–¥834 at Cost of Equity ±1%; ¥811–¥812 at ω ±0.1.

Notes:

• As forecast ROE is below the Cost of Equity, the theoretical value is below Book Value per Share.
• Net assets as of the end of the quarter are used (there is a timing difference relative to the full-year forecast).

(Calculation model: Residual Income Model (Ohlson-type model with an explicit 5-year fade) / Interest rate reference month: 2026-07 / Mechanically calculated solely from publicly disclosed data; this is not a forecast of the market share price or a recommendation of any specific investment action, and does not predict or guarantee future share prices.)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not recommend investment in any specific security. Industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, after consulting with professionals as necessary.

---End of Report---